Novo Nordisk remains a dominant business with a strong pipeline, and current multiples are low enough to justify a buy. Read my latest analysis of NVO stock.
For those who miss Vine, a new project called Divine, backed by Jack Dorsey, is bringing it back from the dead, with over 100 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback